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Abstract
The differentiation of adrenal nodules is wide and varies from primary benign neoplasia, through hormone secreting lesions, to primary 
and secondary malignant masses. With the rapid development of cross-sectional imaging, incidental detection of adrenal nodules has 
become an everyday practice, leaving clinicians with the necessity of further investigation. In this article, we present the current possibili-
ties of adrenal gland imaging and we propose a diagnostic schema for differential diagnosis of incidentaloma. Non-contrast enhanced 
computer tomography (CT) is a modality of choice used for the differential diagnosis of adrenal lesions. It allows the detection of 95% of 
adrenal masses, and the characterisation of most of them. Magnetic resonance imaging (MRI) is a good modality for cases in which CT 
examination cannot determine the character of an adrenal tumour. Nuclear medicine study with the use of Iodine-131 meta iodobenzyl-
guanidine (MIBG) is helpful in the diagnosis of pheochromocytoma. Positron Emission Tomography–Computed Tomography (PET–CT) 
is considered a useful method in patients with a known malignancy history. Ultrasound has a low sensitivity for the detection of small 
lesions and is not capable of reliable characterisation of visualised masses. However, this technique plays an important role in the follow-up 
of non-hypersecreting adrenal lesions. (Pol J Endocrinol 2012; 63 (1): 71–81)
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Streszczenie
Diagnostyka różnicowa guzów nadnerczy jest dość szeroka, od łagodnych, pierwotnych zmian, przez zmiany hormonalnie czynne, aż 
po zmiany złośliwe, pierwotne i wtórne. Wraz z szybkim rozwojem technik obrazowania, codziennością stało się przypadkowe wykrycie 
guzków nadnerczy. Stawia to klinicystę w potrzebie różnicowania tych zmian. W tym artykule przedstawiamy przegląd współczesnych 
możliwości obrazowania gruczołów nadnerczowych oraz proponujemy schemat diagnostyczny w przypadku przypadkowo wykrytego 
guzka nadnercza (tzw. incidentaloma). W zarysie, tomografia komputerowa bez podania środka kontrastowego jest metodą obrazowania 
z wyboru w diagnostyce różnicowej zmian w nadnerczach. Pozwala ona na wykrycie 95% zmian i scharakteryzowanie większości z nich. 
Rezonans magnetyczny jest dobrą techniką u pacjentów, u których nie udało się określić charakteru zmiany za pomocą tomografii kompute-
rowej. Techniki medycyny nuklearnej z zastosowaniem specyficznych znaczników są przydatne w diagnostyce guza chromochłonnego. 
Z kolei stosowanie pozytonowej tomografii emisyjnej jest wskazane u pacjentów z rozpoznaną chorobą nowotworową. Ultrasonografia nie 
pozwala na wykrycie małych zmian oraz nie daje możliwości scharakteryzowania stwierdzonej zmiany, ale jest dobrą i niedrogą techniką 
sprawdzającą się w badaniach kontrolnych. (Endokrynol Pol 2012; 63 (1): 71–81)
Słowa kluczowe: nadnercze, gruczolak nadnarcza, incidentaloma, obrazowanie nadnerczy
Anatomy
Adrenal glands are inverted V- or Y-shaped organs 
located in the retroperitoneal space and composed of 
an outer cortex and an inner medulla. The limbs are 
4 to 5 cm in length and up to 7 mm in thickness, but 
the site of limb connection is always thicker than the 
rest of the adrenal. 
The right adrenal gland lies above the upper pole of 
the right kidney, posterior to the inferior vena cava, me-
dial to the right lobe of the liver and lateral to the right 
diaphragmatic crus. The left adrenal gland lies medial 
and anterior to the upper pole of the left kidney, poste-
rior to the splenic vessels (Figures 1, 2). Because adrenals 
develop independently from kidneys, in case of renal 
ectopy or agenesis, their location remains unchanged. 
It is important to remember that computed tomog-
raphy and magnetic resonance imaging are the only 
modalities which allow imaging of normal adrenals 
in adults. 
Diagnostic methods
Computed tomography
If an adrenal mass is suspected, helical CT is a primary 
modality for its detection and characterisation. Thin 
slices, i.e. of 3 mm or less, are recommended, allow-
ing reliable attenuation measurement even with small 
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lesions. A non-enhanced scan should be performed 
followed by a contrast material-enhanced acquisition 
if necessary, as described later in this chapter [1].
CT allows a precise assessment of such features of 
adrenal tumours as their size, shape, homogeneity, and 
calcifications. The larger the tumour, the greater the risk of 
malignancy. Most masses larger than 5 cm in diameter are 
non-adenomas. Up to 25% of adrenal tumours > 6 cm are 
adrenocortical carcinomas [2]. On the other hand, small 
masses may correspond with adenomas, as well as with 
small carcinomas or pheochromocytomas. The homoge-
neity depends on tumour size and its growth rate: small, 
slowly growing masses tend to be homogenous, whereas 
large, rapidly growing tumours often appear inhomogene-
ous with areas of central necrosis. Change in lesion size 
is also a useful indicator of malignancy. Adenomas may 
also change in size in subsequent examinations, although 
the maximum diameter should not increase by more than 
5 to 6 mm during a one year follow-up [1].
Round and oval shaped masses with smooth mar-
gins are often benign; however, small pheochromocyto-
mas and metastases usually have the same appearance. 
Irregular shape usually indicates malignancy.
Calcifications are more often present in adrenal car-
cinomas, but may also be visible in other lesions such 
as neuroblastoma or tuberculosis.
When invasion of surrounding anatomic structures 
is present, the diagnosis of adrenocortical carcinoma is 
most likely.
Attenuation at non-enhanced CT
Most adenomas contain intracellular lipids and thus have low 
attenuation at non-enhanced CT scans (Figure 3). Therefore, 
attenuation measurement is currently the most important 
parameter used to differentiate benign adenomas from 
malignant adrenal masses. When measuring attenuation 
with the use of region of interest (ROI), it should be as large 
as possible but without inclusion of the lesion’s margins 
or retroperitoneal fat. Boland et al., in a meta-analysis 
of ten studies, determined an optimal threshold value 
Figure 1. Non-contrast enhanced CT, axial plane. Normal adrenal 
glands
Rycina 1. Tomografia komputerowa bez dożylnego podania środka 
cieniującego, płaszczyzna poprzeczna. Prawidłowe gruczoły 
nadnerczowe
Figure 2. Non-contrast enhanced CT, coronal plane. Normal 
adrenal glands
Rycina 2. Tomografia komputerowa bez dożylnego podania 
środka cieniującego, płaszczyzna czołowa. Prawidłowe gruczoły 
nadnerczowe
Figure 3. Non-contrast enhanced CT, axial plane. Low attenuation 
right adrenal mass (star) consistent with a lipid-rich adenoma
Rycina 3. Tomografia komputerowa bez dożylnego podania środka 
cieniującego, płaszczyzna poprzeczna. Guzek prawego nadnercza 
o niskiej gęstości (gwiazdka) odpowiadający gruczolakowi o dużej 
zawartości tłuszczu
*
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of +10 Hounsfield Units (HU), which allows obtaining 
a 71% sensitivity and 98% specificity for the diagnosis of 
adrenal adenomas [3]. 
On the other hand, myelolipoma, a tumour com-
posed mainly of fatty tissue, contains areas with a den-
sity lower than –50 HU, far below the density typical 
for adenomas. Distinguishing between these two lesions 
is straightforward with unenhanced CT (Figure 4) [4].
To conclude, a finding of an adrenal mass of a density 
lower than +10 HU on a non-contrast enhanced CT scan 
allows a confident diagnosis of adenoma, and does not 
require further investigation. Using this threshold value, 
a false positive diagnosis will happen rarely (2%), and 
may be related to the presence of infrequent adrenal 
cystic lesions.
Among the tumours which present with an attenu-
ation higher than +10 HU, adenomas are still the most 
frequent lesions. Higher attenuation is related to lower 
lipid content. Lipid-poor adenomas represent 10–40% 
of adenomas [5]. Apart from lipid-poor adenomas, the 
most frequent adrenal masses with an attenuation 
higher than +10 HU are: metastases, pheochromocy-
tomas and adrenocortical carcinomas (Figures 5, 6). In 
these tumours, non-enhanced CT is insufficient and 
they require further investigation [6].
Contrast media washout
Another CT technique successfully used for the differ-
entiation of adrenal masses is assessment of washout 
of intravenously administered contrast material (CM). 
Adenomas, as well as other tumours, enhance rapidly 
after CM injection, but due to perfusion differences 
the washout of CM from adenomas is relatively rapid 
compared to other adrenal lesions, which demonstrate 
significantly slower washout. 
In a case of adenoma attenuation, values gradu-
ally return to the level of non-enhanced examination 
5–45 minutes after CM injection. Other lesions, such 
as adrenocortical carcinomas, metastases and pheo-
chromocytomas enhance rapidly, but then maintain 
Figure 5. Unenhanced CT scan. Bilateral adrenal metastases from 
lung cancer demonstrating density above +30 HU
Rycina 5. Tomografia komputerowa bez dożylnego podania środka 
cieniującego. Obustronne przerzuty z raka płuca przedstawiające 
gęstość powyżej +30 j.H.
Figure 6. Unenhanced CT scan. The right adrenal mass 
demonstrating density above +30 HU and central calcifications 
— adrenocortical carcinoma
Rycina 6. Tomografia komputerowa bez dożylnego podania środka 
cieniującego. Guz prawego nadnercza o gęstości powyżej +30 j.H. 
zawierający zwapnienia — rak kory nadnerczy
Figure 4. Non-contrast enhanced CT, axial plane image shows 
a right adrenal mass (star) of a very low attenuation (below 
–50 HU) similar to retroperitoneal fat, which is consistent with 
a myelolipoma
Rycina 4. Tomografia komputerowa bez dożylnego podania 
środka cieniującego, płaszczyzna poprzeczna. Obraz przedstawia 
guz prawego nadnercza o bardzo niskiej gęstości, zbliżonej do 
gęstości tłuszczu przestrzeni zaotrzewnowej (poniżej –50 j.H.), 
odpowiadający myelolipoma
*
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relatively higher attenuation values. This phenomenon 
is probably related to increased perfusion and vessel 
permeability in these tumours, causing marked contrast 
media diffusion to the extracellular space and, in con-
sequence, prolonged accumulation. The assessment of 
contrast media washout is most frequently performed 
10–15 minutes after injection, which usually allows dif-
ferentiation of lipid-rich and lipid-poor adenomas from 
other adrenal tumours (Figure 7) [7].
Three parameters are used in the differential diag-
nosis of adrenal tumours using washout assessment: 
 — Attenuation value at delayed contrast enhanced 
CT images (usually 10–15 minutes after contrast 
injection);
 — Absolute percentage washout (APW) (attenuation 
values of non-enhanced, 1 minute and 10–15 min-
utes delayed images are required);
 — Relative percentage washout (RPW) (attenuation 
values of 1 minute and 10–15 minutes delayed im-
ages are required, non-enhanced examination is 
not necessary). 
Attenuation value at delayed CT depends on the 
amount of intravenous contrast media and time from 
the beginning of injection. A Hounsfield unit of less than 
+35 at 10–15 minutes delayed CT is highly indicative 
of adrenal adenoma. 
Absolute percentage washout (APW) is calculated 
using the following formula: 
Figure 7. CT contrast media washout assessment, axial plane, 
pre-contrast (a); portal venous phase (b); and 15-minutes delayed 
phase (c). CT images show a well-defined right adrenal mass (star). 
The attenuation measurements demonstrate marked contrast media 
washout (> 50%) consistent with an adenoma
Rycina 7. Tomografia komputerowa, ocena wypłukiwania środka 
cieniującego. Faza badania przed podaniem środka cieniującego (a), 
faza wrotna (b), faza opóźniona 15 min (c). Obrazy przedstawiają 
dobrze odgraniczony guz prawego nadnercza (gwiazdka). Pomiary 
współczynnika osłabienia promieniowania przedstawiają istotne 
wypłukiwanie się środka cieniującego (> 50%) charakterystyczne 
dla gruczolaka
* *
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[(1 min. delayed enhanced HU value – 10 min. delayed 
enhanced HU value) / (1 min. delayed enhanced HU value 
– non-enhanced HU value)] × 100% 
Absolute percentage washout values are greater for 
adenomas than for other adrenal tumours. Multicentre 
analysis has revealed an optimal threshold value of 50% 
for a 10-minute delayed CT. Values greater than 50% are 
typical for adenomas. This method allows differential 
diagnosis of adenomas and non-adenomas with high 
sensitivity and specificity, 98% and 92% respectively [7].
Relative percentage washout (RPW) is calculated 
using the following formula:
[(1 min. delayed enhanced HU value – delayed enhanced 
HU value) / (delayed enhanced HU value)] × 100% 
According to several authors, RPW is as effective as 
APW. For a 10-minute delayed CT, values greater than 
40% are typical for adenomas. The higher this param-
eter is, the greater the accuracy of the method. This 
method is used most frequently when adrenal mass 
is incidentally found during contrast-enhanced CT 
examination performed for other indications (without 
non-enhanced phase).
Potential interpretation difficulties may appear in 
a case of adrenal hyperplasia, especially when a single 
dominant nodule is present. A nodule is usually less 
than 3 cm in diameter and on CT scans it may present 
the same attenuation values as adrenal adenoma. 
A comparative assessment to the opposite adrenal is 
useful in these cases. In a case of hyperplasia, the con-
tralateral adrenal gland is also markedly prominent, 
whereas in a case of non-hyperfunctioning adenoma, 
the contralateral adrenal has usually a normal ap-
pearance. When an adenoma is hyperfunctioning, the 
contralateral gland is often atrophic.
Additionally, contrast-enhanced CT study without 
assessment of washout may be useful in several situ-
ations. In a case of suspected adrenal haemorrhage, 
attenuation values of adrenal mass on unenhanced 
CT scans exceed +10 HU. After contrast administra-
tion, these lesions, unlike other hyper-attenuating 
adrenal masses, do not show significant contrast 
enhancement. Patients with adrenal cysts usually 
demonstrate a homogenous water-density mass (with 
attenuation in the range of adrenal adenoma), which, 
on contrast enhanced CT scans, does not show any 
enhancement. Contrast-enhanced CT study may 
also be useful in patients with adrenal metastases 
and adrenal carcinoma for the evaluation of possible 
metastatic liver lesions. 
CT — conclusion
Patients referred for CT for a suspected adrenal tumour 
should initially undergo a non-contrast enhanced 
study. If normal adrenals are demonstrated, an adrenal 
tumour may be excluded and no further examina-
tions are needed. A finding of an adrenal tumour with 
an attenuation value lower than +10 HU allows the 
confident diagnosis of adrenal adenoma, and no further 
investigation is required. 
However, finding an adrenal mass with an attenua-
tion greater than +10 HU requires further procedures, 
such as contrast enhanced CT with early (1-minute de-
layed) and 10-minute delayed phases, with subsequent 
attenuation value measurement and evaluation of CM 
washout (APW). When a lesion is incidentally found 
on contrast-enhanced CT, an additional 10-minute 
delayed phase may be performed and a relative per-
centage washout (RPW) of the contrast material may 
be assessed. 
CM washout may also be assessed with magnetic 
resonance imaging (MRI), although this method is used 
rarely. Another MRI technique, chemical shift imaging, 
is frequently used in a case of undetermined (on un-
enhanced CT) adrenal masses and demonstrates high 
accuracy for their characterisation. 
In conclusion, the main advantages of CT are high 
sensitivity in the detection of adrenal lesions and high 
sensitivity and specificity in differentiating between 
benign and malignant masses. CT is a primary modal-
ity for the detection and characterisation of adrenal 
masses and is useful in the verification of ultrasound 
(US) findings.
Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) is used frequently 
for characterising adrenal lesions in cases in which CT 
examinations are equivocal. A standard MRI study of 
adrenal glands consists of non-contrast enhanced se-
quences. Only in certain cases may contrast-enhanced 
examination be helpful (e.g. adrenal haemorrhage, cyst, 
carcinoma, metastases). 
MRI allows the detection of adrenal masses with 
a similar sensitivity as CT. Several MRI parameters, 
such as signal intensity on T2-weighted images or 
enhancement rates were used in the past, but today 
the most important role in the description of adrenal 
masses is played by chemical shift imaging. This tech-
nique, similar to non-enhanced CT attenuation values 
measurement, relies on the detection of lipids within 
an adrenal mass (indicative of an adenoma), although 
it is more sensitive for the identification of intracellular 
lipids [8]. It is based on the T1 gradient echo technique, 
which allows acquiring of so called in-phase and 
out-of-phase images. 
Only adenomas and myelolipomas may demon-
strate relative loss of signal intensity on out-of-phase 
images (Figure 8); however, many myelolipomas do 
not contain enough water in the fatty tissue to cause 
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a visible signal drop. Nevertheless, MRI diagnosis of 
myelolipoma is straightforward and is based on the 
use of fat saturated images acquired with sequences 
applying spectral fat saturation or inversion recovery 
technique (Figure 9). Chemical shift imaging allows 
the differentiation of adenomas from other tumours 
in 90% of cases. However, similarly to CT, it does not 
allow differentiation between other masses such as 
metastases, adrenocortical carcinomas or pheochro-
mocytomas [9]. 
Figure 9. MR T2 weighted images without and with fat saturation show a well-defined large right adrenal mass (star), which consists 
mainly of fatty tissue (signal intensity loss on fat saturated image). This appearance is typical for myelolipoma
Rycina 9. Rezonans magnetyczny, obrazy T2-zależne bez i z saturacją tkanki tłuszczowej, przedstawiają dobrze odgraniczoną masę 
(gwiazdka), która zawiera głównie tkankę tłuszczową (spadek intensywności sygnału w obrazach z saturacją tkanki tłuszczowej) — 
obraz typowy dla myelolipoma
Figure 8. MR T1 gradient echo in-phase and out-of-phase images, axial plane. Well-defined left adrenal mass, which shows marked 
relative signal intensity loss on out-of-phase images, indicative of fatty content — appearance consistent with adrenal adenoma
Rycina 8. Rezonans magnetyczny, obrazy T1-zależne echa gradientowego w fazie oraz w przeciwfazie, płaszczyzna poprzeczna. Dobrze 
odgraniczony guz lewego nadnercza, przedstawiający istotny spadek intensywności sygnału w obrazach w przeciwfazie, oznaczający 
tłuszczową zawartość zmiany — obraz charakterystyczny dla gruczolaka
**
77
Endokrynologia Polska/Polish Journal of Endocrinology 2012; 63 (1)
SZ
K
O
LE
N
IE
PO
D
Y
PL
O
M
O
W
E
Qualitative as well as quantitative analysis of signal 
intensity is used for the evaluation of adrenal lesions 
on in-phase and out-of-phase images. In most cases, 
qualitative analysis is sufficient for the differentiation 
of tumours that contain fat from those that do not. On 
out-of-phase images, there is loss of signal intensity in 
adenomas, while in nonadenomas signal intensity does 
not change significantly [10].
In the rare cases in which loss of signal intensity is 
unclear, quantitative analysis should be performed. Sev-
eral studies have shown that among methods used for 
quantitative analysis, signal intensity index is the most 
accurate. It is calculated using the following formula: 
[(SI in-phase – SI out-of-phase) / SI in-phase] × 100%
An SI index greater than 16 is strongly indicative of 
an adenoma. 
Even though differentiation of adrenal tumours on 
chemical-shift MRI, as well as on non-enhanced CT im-
ages, is based on lipid contents of adenomas, it has been 
shown that MRI is more sensitive for intracellular lipid 
detection than CT. Heider et al. performed a retrospec-
tive analysis of adrenal lesions with attenuation of more 
than +10 HU at non-enhanced CT, which subsequently 
underwent MRI examination [11]. 
Among adrenal tumours with attenuation values 
between +10 and +30 HU at non-enhanced CT, MRI 
was effective in 89%, enabling detection of small 
amounts of fat in these low-lipid adenomas. However, 
in cases of adenomas containing minimal or no fat, 
with attenuation values of more than +30 HU, MRI 
was ineffective [11].
Similarly to CT, evaluation of contrast material wash-
out may also be employed during MRI, although this 
method is used rarely.
Another advantage of MRI is the possibility of the 
identification of some pheochromocytomas, showing 
characteristic high signal intensity on T2-weighted 
images (Figure 10). Furthermore, MRI is useful in the 
detection of extra-adrenal pheochromocytomas.
In conclusion, in adrenal masses presenting with 
attenuation values from +10 to +30 HU, chemical shift 
MRI is an efficient and accurate method, which may 
be applied for their characterisation instead of contrast 
media washout assessment with CT. The effectiveness 
of chemical shift MRI in differentiating adenomas from 
non-adenomas approaches 90%, and is thought to be 
only slightly lower than assessment of contrast media 
washout with CT (Figure 11). 
Ultrasound
Ultrasound, compared to other techniques such as MRI 
and CT, is a relatively inexpensive and portable modal-
ity. Because of its wide prevalence, it is commonly used 
and often leads to the detection of non-symptomatic 
Figure 10. MR T2 weighted images without and with fat saturation show a well-defined, large, heterogeneous right adrenal mass 
(star), which does not demonstrate signal intensity loss on fat saturated image. The final diagnosis (based on surgery specimen) was 
pheochromocytoma
Rycina 10. Rezonans magnetyczny, obrazy T2-zależne bez i z saturacją tkanki tłuszczowej, przedstawiają dobrze odgraniczoną, 
heterogenną masę (gwiazdka), której sygnał nie ulega obniżeniu w obrazach z saturacją tkanki tłuszczowej. Na podstawie badania 
histopatologicznego rozpoznano guz chromochłonny
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Figure 11. T2-weighted MR image showing right adrenocortical 
carcinoma and metastatic lesions in the liver
Rycina 11. Rezonans magnetyczny, obrazy T2 zależne 
przedstawiają raka kory prawego nadnercza z przerzutami do 
wątroby
adrenal tumours (incidentaloma). Non-symptomatic 
adrenal masses occur in 2–5% of the population. The 
sensitivity of this technique in the detection of adrenal 
masses is approximately 76%, with specificity around 
92%. The sensitivity is lower in cases of masses located 
in the left adrenal gland, those smaller than 20 mm, and 
in obese patients. 
The evaluation of the left adrenal gland with 
ultrasound is frequently difficult due to its location 
(posterior to the stomach and small bowel). Not 
infrequently, some anatomic structures may be dem-
onstrated in adrenal fields and incorrectly diagnosed 
as adrenal masses (a false positive diagnosis) (Table I). 
In adults, normal adrenals are not visualised in the 
vast majority of patients and therefore small lesions 
are difficult to exclude, leading to a false negative 
diagnosis in some cases. 
Ultrasound enables the measurement of larger 
masses (> 20 mm); however, differential diagnosis based 
solely on tumour size is impossible. Benign adenomas 
are usually small (< 50 mm), but some metastases and 
pheochromocytomas may be similar in size, which 
makes differentiation unfeasible.
Diagnostic difficulties especially concern patients 
with a primary extra-adrenal neoplasm accompanied 
by adrenal mass. Adrenal tumours visualised in these 
patients are as often metastases as benign adenomas; 
therefore their distinction is of the utmost importance 
and may be crucial for treatment planning.
When a larger adrenal mass (> 50 mm) is detected, 
metastases, pheochromocytomas, adrenocortical 
carcinomas as well as benign adenomas have to be 
taken into consideration in differential diagnosis. In 
malignant tumours and larger pheochromocytomas, 
low-echogenicity areas of necrosis may be present.
Because almost all adrenal masses are hypoechoic, 
this parameter is also not useful for their characterisa-
tion. A rare but important exception is hyperechoic 
myelolipoma, which requires differentiation from other 
retroperitoneal tumours containing fatty tissue, such as 
lipoma, liposarcoma and teratoma. Another adrenal le-
sion that may be hyperechogenic is adrenal haematoma. 
Its echogenicity depends on the time since haemor-
rhage. Early on, hyperechogenicity is characteristic, but 
later this lesion usually transforms into a hypoechogenic 
pseudocyst.
Another uncommon lesion, but with typical ultra-
sound appearance, is adrenal cyst, which has the ap-
pearance of a well-defined non-echogenic lesion with 
posterior acoustic enhancement. However, despite typical 
morphology, technical problems with adrenal visualisation 
in many patients mean that differentiation between a solid 
and a cystic adrenal mass may be difficult.
In conclusion, one of the main disadvantages of 
ultrasound is low sensitivity in the detection of adrenal 
masses smaller than 20 mm. Other disadvantages are: 
difficulties in assessment of adrenal fields in obese pa-
tients, and lack of accurate criteria for the discrimination 
of adrenal masses. The main advantage of ultrasound 
is its wide prevalence. Therefore it is considered to be 
a good modality for the follow-up (with size evaluation) 
of non-symptomatic lesions greater than 20–30 mm. 
Nuclear medicine
Adrenal cortical scintigraphy is rarely useful compared 
to modern CT and MRI technology, which are far more 
Table I. Adrenal pseudotumours in ultrasound examination
Tabela I. Pseudoguzy nadnerczy w badaniu ultrasonograficznym
Bilateral lesions Tumours of upper renal poles
Cystic lesions of upper renal poles
Right adrenal field Hepatic flexure
Dilated inferior vena cava
Focal liver lesion
Left adrenal field Splenic lobe/accessory spleen
Dilated, curved splenic vessels 
Splenic artery aneurysm
Pancreatic tail 
Gastric diverticulum
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sensitive in the detection of small masses. A primary ra-
diopharmaceutical used in the differentiation of adrenal 
lesions is NP-59 (6-beta-iodomethyl-19norcholesterol), 
which is a cholesterol analogue effective in the identifica-
tion of adrenocortical tumours secreting glucocorticoids, 
mineralocorticoids and androgens (non-symptomatic 
adenomas usually also secrete small amounts of hormones, 
therefore radiopharmaceutical uptake is also present). 
This diagnostic tool has a high sensitivity and specificity 
in the diagnosis of adrenal adenoma, thus lesions with 
no uptake are diagnosed as non-adenomas. However, 
adrenal cortical scintigraphy has many disadvantages: 
low effectiveness in the detection of masses smaller than 
20 mm, thyroid blockage with Lugol’s iodine, and high 
absorbed radiation dose [3].
In contrast to adrenal cortical scintigraphy, MIBG 
(Iodine-131 meta iodobenzylguanidine) is still very 
useful in the diagnosis of adrenal medullary neoplasms 
such as pheochromocytoma, paraganglioma, and neu-
roblastoma. Any uptake of MIBG by the adrenal gland 
is abnormal. This technique is especially useful in cases 
when pheochromocytoma is suspected, but no adrenal 
mass is identified on CT or MRI, meaning that extra-ad-
renal localisation is probable. MIBG scintigraphy may 
also be used to detect metastatic disease of any above-
-mentioned neoplasm or residual tumour after surgery. 
The disadvantages of this examination include thyroid 
blockage and a long time between radiopharmaceutical 
admission and examination (24–48 h) [12]. 
Positron Emission Tomography–
–Computed Tomography (PET–CT)
PET-CT is an imaging modality which combines 
Positron Emission Tomography (PET) and computed 
tomography (CT). Data from both devices is acquired 
simultaneously, in the same session and combined 
into a single image. Therefore functional imaging of 
radiopharmaceutical uptake, which shows the spatial 
distribution of metabolic activity in the body, can be cor-
related more precisely with anatomic imaging obtained 
by CT scanning.
It has been shown in multiple studies that malig-
nancies are usually more metabolically active than 
benign tumours. For the purpose of differentiation of 
an adrenal mass, adrenal uptake of fluorodeoxyglu-
cose (FDG) is compared to hepatic uptake if greater 
adrenal mass is considered to be of malignant origin. 
However, further differentiation between malignan-
cies is impossible. Moreover, an adrenocortical carci-
noma may be metabolically not active, and the results 
may be false-negative. The analysis of standardised 
uptake value (SUV) may also be combined with at-
tenuation values assessment from unenhanced CT 
(with < 10 HU positive for adenoma). In addition, 
no significant difference was found in radiophar-
maceutical uptake between lipid-rich and lipid-poor 
adenomas [13]. 
Increased FDG uptake in inflammatory adrenal 
lesions such as sarcoidosis, tuberculosis, adrenal en-
dothelial cyst, some adrenal adenomas, periadrenal 
abnormality or adrenal cortical hyperplasia, may lead 
to a false positive diagnosis of malignancy. On the 
other hand, false negative results may be related to 
haemorrhage and necrosis in the metastatic tumour. 
Also, metastases from tumours that do not have FDG 
avid uptake, such as neuroendocrine tumours and 
bronchioloalveolar carcinoma, may yield false negative 
results on PET-CT [14]. 
In conclusion, FDG PET is a promising new tech-
nique which may be useful in differentiating between 
malignant (metastatic) lesions and benign adenomas 
in patients with known extra-adrenal malignancy; 
however, it does not allow differentiation between 
malignant lesions.
Adrenal vein sampling
Adrenal vein sampling is a procedure rarely per-
formed in patients with primary aldosteronism. This 
diagnostic method is considered to be a difficult 
procedure. However, some authors believe that there 
may be an increased demand for such examination 
due to data showing that primary aldosteronism is 
more common than previously thought [15]. The 
examination technique is similar to venography, 
and consists of adrenal veins catheterisation and 
blood sampling after adrenocorticotropic hormone 
(ACTH) stimulation. CT examination performed prior 
to sampling is useful in procedure planning in terms 
of demonstrating the anatomy and positions of the 
adrenal veins.
Adrenal vein blood analysis may demonstrate 
unilateral or bilateral hormone secretion after ACTH 
stimulation, which allows differentiation between 
adrenal cortical hyperplasia and secreting adenoma. 
Secreting adenoma will cause a unilateral aldosterone 
secretion, whereas bilateral secretion will be present 
in adrenal cortical hyperplasia [16]. As adrenal corti-
cal hyperplasia can demonstrate several appearances 
including macronodular, differential diagnosis with 
secreting adenoma in cases of primary aldosteronism is 
vital, mainly because patients with secreting adenoma 
may be offered surgery. 
In conclusion, adrenal vein sampling is an invasive 
and demanding procedure. However, in selected cases 
there is no alternative for differentiation between prima-
ry adrenal lesion and adrenal hyperplasia. Performed 
in experienced institutions, it allows for differential 
diagnosis between these two.
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Biopsy
Adrenal biopsy is indicated especially in cases when 
an extra-adrenal tumour is present and a co-existing 
adrenal lesion cannot be accurately differentiated by 
CT, MRI or PET imaging. In such cases, the probability 
of metastasis is nearly as high as adrenal adenoma. 
Differentiation between those two lesions is vital for 
patients with no other metastasis confirmed [17]. 
Biopsy is an ultrasound-guided or CT-guided pro-
cedure performed with a thin needle (usually 22 G). 
Pheochromocytoma and coagulation disorders must 
be excluded before the procedure. For the right adrenal 
biopsy, a posterior or transhepatic approach is used, while 
for the left adrenal, a posterior or, rarely, transgastral ap-
proach is possible. The thin needle biopsy technique has 
a low complication rate. Complications that can appear are: 
bleeding, pneumothorax, pancreatitis and sepsis.
Summary
Non-contrast enhanced CT is a primary modality for the 
diagnosis of adrenal lesions (Figure 12). It allows detec-
tion of 95% of adrenal masses, and characterisation of 
most of them. Magnetic Resonance Imaging is a good 
modality for cases in which CT examination is unable 
to determine an adrenal tumour’s character; we are 
Figure 12. Suggested evaluation of an adrenal incidentaloma [18, 19]; *metastasectomy should be considered in the case of an isolated 
adrenal metastatic lesion; **all hormonally active lesions (especially pheochromocytomas) require appropriate pharmacological treatment 
before surgery; ***there is no consensus on appropriate follow-up evaluation. The first imaging re-evaluation may be performed early 
(after 3–6 months). Afterwards, imaging re-evaluation may be performed annually for 2–4 years. Biochemical re-evaluation should be 
performed annually for 3–5 years. Should the tumour extensively grow or become hormonally active during follow-up, adrenalectomy 
should be considered; US — ultrasonography; CT — computed tomography; MR — magnetic resonance; HU — Hounsfield units
Rycina 12. Sugerowany schemat postępowania w przypadkowo wykrytych guzach nadnerczy [18, 19]; *w przypadku pojedynczego 
ogniska przerzutowego w nadnerczach należy rozważyć metastazektomię; **wszystkie guzy hormonalnie czynne (zwłaszcza guz 
chromochłonny) wymagają odpowiedniego leczenia farmakologicznego przed zabiegiem chirurgicznym; ***nie ma jednoznacznych 
ustaleń dotyczących dalszej obserwacji chorych. Kolejne badania obrazowe można przeprowadzić po niedługim czasie (po 3–6 miesiącach), 
a następnie powtarzać je corocznie przez 2–4 lata. Badania biochemiczne należy przeprowadzać raz do roku przez 3–5 lat. W przypadku 
gdy późniejsze badania wykażą wzrost guza lub gdy stanie się on hormonalnie czynny, należy rozważyć adrenalektomię; US — 
ultrasonografia; CT — tomografia komputerowa; MR — rezonans magnetyczny; HU — jednostki Hounsfield
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here referring to masses with attenuation values from 
+10 to +30 HU at non-enhanced CT. Adrenal cortical 
scintigraphy has not received general recognition in 
the differential diagnosis of adrenal masses. However, 
nuclear medicine study with the use of MIBG is effective 
in the diagnosis of an extra-adrenal pheochromocytoma. 
PET-CT is considered a useful method for differentiat-
ing between malignant (metastatic) lesions and benign 
adenomas in patients with known malignancy history. 
Adrenal biopsy is indicated rarely in patients with 
known neoplastic disease and a co-existing adrenal le-
sion, which cannot be accurately differentiated by CT, 
MRI or PET imaging. Ultrasound, due to its availability 
and low cost, allows the detection of a large number of 
adrenal tumours. However, it has low sensitivity for the 
detection of small (< 2 cm) lesions, and is not capable of 
reliable characterisation of visualised masses. However, 
this technique plays an important role in the follow-up 
of non-hypersecreting adrenal lesions. 
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